Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan

March 6, 2020checkorphan

Learn more about:

Whooping cough

Related Clinical Trial

Brief Title

Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan

Official Title

Immunogenicity and Safety of ADACEL™ (TdcP Vaccine) as Fifth Dose in Children 6-8 Years of Age.

Brief Summary

      To assess the immunogenicity profile of ADACEL™, Tetanus and Diphtheria Toxoids Adsorbed
      combined with Component Pertussis Vaccine (TdcP Vaccine) one month after administration.

      To describe the safety profile of ADACEL™ (TdcP Vaccine) when given as a fifth dose.

Study Phase

Phase 3

Study Type

Interventional

Primary Outcome

Percentage of Participants With Antibody (Anti-diphtheria, Anti-tetanus, and Anti-pertussis Toxoids) Responses Pre- and Post-vaccination

Secondary Outcome

 Percentage of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination

Condition

Diphtheria

Intervention

Diphteria, tetanus, and Acellular Pertussis vaccine

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Biological

Estimated Enrollment

Start Date

November 2005

Completion Date

August 2006

Primary Completion Date

August 2006

Eligibility Criteria

        Inclusion Criteria:

          -  Aged from 6 to 8 years on the day of inclusion

          -  Informed consent form (ICF) signed by parent(s)/legal representative

          -  Able to attend all scheduled visits and to comply with all trial procedures

          -  Written documentation of complete primary series and fourth dose of Diphtheria,
             Tetanus toxoids and whole cell Pertussis vaccine (DTP)

          -  Parent(s)/legal representative present or fully completed pre-inclusion medical
             questionnaire

        Exclusion Criteria:

          -  Participation in another clinical trial in the 4 weeks preceding the trial vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer
             chemotherapy or radiation therapy within the preceding 6 months, or long term systemic
             corticosteroids therapy

          -  Systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to the trial vaccine or a vaccine containing the same
             substances with specific focus on subjects who had, after previous administration of
             DTP or diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine, one of
             the following adverse events

               1. encephalopathy not attributable to another identifiable cause within 7 days of
                  administration of a previous dose

               2. temperature of > 40.5 °C within 48 hours not due to another identifiable cause

               3. collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours

               4. persistent, inconsolable crying lasting > 3 hours, occurring within 48 hours

               5. seizure with or without fever occurring within 3 days

          -  Chronic illness at a stage that could interfere with trial conduct or completion.

          -  Blood or blood-derived products received in the past 3 months

          -  Any vaccination in the 4 weeks preceding the trial vaccination (except Oral
             Poliomyelitis Vaccine [OPV])

          -  Any vaccination planned during the present trial period (except OPV)

          -  History of diphtheria and/or tetanus and/or pertussis infection (confirmed either
             clinically, serologically or microbiologically)

          -  Previous fifth vaccination against diphtheria and/or tetanus and/or pertussis
             infection with the trial vaccine or another vaccine

          -  Clinical or serological evidence of systemic illness including Hepatitis B, C or Human
             Immunodeficiency Virus (HIV)

          -  Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination

          -  History of/current seizures

          -  Febrile illness (axillary temperature ≥ 37.4 °C) or acute illness on the day of
             inclusion

Gender

All

Ages

6 Years - 8 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Medical Director, ,

Location Countries

Taiwan

Location Countries

Taiwan

Administrative Informations

NCT ID

NCT00258908

Organization ID

TD521

Responsible Party

Sponsor

Study Sponsor

Sanofi Pasteur, a Sanofi Company

Study Sponsor

Medical Director, Study Director, Sanofi Pasteur Inc

Verification Date

April 2016